Google+

Alzheimer’s Drug Makes a Comeback

The pharma company claims a previous decision to discontinue research into the drug was based on incomplete Phase 3 trial data and new analysis has revealed significant success
The pharma company claims a previous decision to discontinue research into the drug was based on incomplete Phase 3 trial data and new analysis has revealed significant success

In a stunningly unusual turn of events a new Alzheimer’s drug, previously declared a failure back in March, has been resurrected with the pharmaceutical company behind the treatment suggesting the earlier decision to discontinue the research was premature and based on incorrect data analysis. read more

Bad News for Alzheimer’s Sufferers

Biogen has abandoned late-stage clinical trials for a previously promising Alzheimer's drug
Biogen has abandoned late-stage clinical trials for a previously promising Alzheimer’s drug(Credit: AndrewLozovyi/Depositphotos)

A shockwave reverberated through the Alzheimer’s research community today after pharmaceutical company Biogen announced it was discontinuing two massive final phase human trials into the previously promising Alzheimer’s drug aducanumab. The announcement is the latest in a long line of failed Alzheimer’s drugs targeting the popular amyloid protein hypothesis. read more